TYK2 and psoriasis: In a mouse model of imiquimod-induced psoriasis-like dermatitis, IL-17 and IL-22 secreted from γδ T cells and Th17 upon IL-23 stimulation were involved in skin inflammation and keratinocyte activation, which were improved by TYK2 inhibitor treatment20,25.